High-level expression of wild-type p53 in melanoma cells is frequently associated with inactivity in p53 reporter gene assays

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Houben, Roland ^a   Hesbacher, Sonja ^a   Schmid, Corinna P ^a   Kauczok, Claudia S ^a   Flohr, Ulrike ^a   Haferkamp, Sebastian ^a   Müller, Cornelia S L ^c   Schrama, David ^a,d   Wischhusen, Jörg ^b   Becker, Jürgen C ^d  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

^d MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN P53; SHORT HAIRPIN RNA;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE S PHASE; CONTROLLED STUDY; DNA EXTRACTION; EXON; GENE MUTATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MELANOCYTE; MELANOMA CELL; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; REPORTER GENE; SEQUENCE ANALYSIS; TRANSCRIPTION INITIATION; CELL CYCLE; GENETIC PROCEDURES; GENETICS; MELANOMA; METABOLISM; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; SKIN TUMOR; TUMOR CELL LINE;

BASE SEQUENCE; CELL CYCLE; CELL LINE, TUMOR; DNA MUTATIONAL ANALYSIS; GENES, REPORTER; GENETIC TECHNIQUES; HUMANS; MELANOMA; MOLECULAR SEQUENCE DATA; MUTATION; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79960089162     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022096     Document Type: Article

References (43)

1. Song H, Xu Y, (2007) Gain of function of p53 cancer mutants in disrupting critical DNA damage response pathways. Cell Cycle 6: 1570-1573.
2. Green DR, Chipuk JE, (2006) p53 and metabolism: Inside the TIGAR. Cell 126: 30-32.
3. Blagosklonny MV, (1997) Loss of function and p53 protein stabilization. Oncogene 15: 1889-1893.
4. Lavin MF, Gueven N, (2006) The complexity of p53 stabilization and activation. Cell Death Differ 13: 941-950.
5. Sherr CJ, (2006) Divorcing ARF and p53: an unsettled case. Nat Rev Cancer 6: 663-673.
6. Roemer K, (1999) Mutant p53: gain-of-function oncoproteins and wild-type p53 inactivators. Biol Chem 380: 879-887.
7. van Oijen MG, Slootweg PJ, (2000) Gain-of-function mutations in the tumor suppressor gene p53. Clin Cancer Res 6: 2138-2145.
8. Crook T, Tidy JA, Vousden KH, (1991) Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell 67: 547-556.
9. Michael D, Oren M, (2002) The p53 and Mdm2 families in cancer. Curr Opin Genet Dev 12: 53-59.
10. Vousden KH, Lu X, (2002) Live or let die: the cell's response to p53. Nat Rev Cancer 2: 594-604.
11. Nikolaev AY, Li M, Puskas N, Qin J, Gu W, (2003) Parc: a cytoplasmic anchor for p53. Cell 112: 29-40.
12. Grob TJ, Novak U, Maisse C, Barcaroli D, Luthi AU, et al. (2001) Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ 8: 1213-1223.
13. Bergamaschi D, Samuels Y, O'Neil NJ, Trigiante G, Crook T, et al. (2003) iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat Genet 33: 162-167.
14. Terzian T, Torchia EC, Dai D, Robinson SE, Murao K, et al. (2010) p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation. Pigment Cell Melanoma Res 23: 781-794.
15. Albino AP, Vidal MJ, McNutt NS, Shea CR, Prieto VG, et al. (1994) Mutation and expression of the p53 gene in human malignant melanoma. Melanoma Res 4: 35-45.
16. Castresana JS, Rubio MP, Vazquez JJ, Idoate M, Sober AJ, et al. (1993) Lack of allelic deletion and point mutation as mechanisms of p53 activation in human malignant melanoma. Int J Cancer 55: 562-565.
17. Daniotti M, Oggionni M, Ranzani T, Vallacchi V, Campi V, et al. (2004) BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene 23: 5968-5977.
18. Ragnarsson-Olding BK, Karsberg S, Platz A, Ringborg UK, (2002) Mutations in the TP53 gene in human malignant melanomas derived from sun-exposed skin and unexposed mucosal membranes. Melanoma Res 12: 453-463.
19. Zerp SF, van Elsas A, Peltenburg LT, Schrier PI, (1999) p53 mutations in human cutaneous melanoma correlate with sun exposure but are not always involved in melanomagenesis. Br J Cancer 79: 921-926.
20. Papp T, Jafari M, Schiffmann D, (1996) Lack of p53 mutations and loss of heterozygosity in non-cultured human melanocytic lesions. J Cancer Res Clin Oncol 122: 541-548.
21. Box NF, Terzian T, (2008) The role of p53 in pigmentation, tanning and melanoma. Pigment Cell Melanoma Res 21: 525-533.
22. Kern SE, Winter JM, (2006) Elegance, silence and nonsense in the mutations literature for solid tumors. Cancer Biol Ther 5: 349-359.
23. Aylon Y, Oren M, (2007) Living with p53, dying of p53. Cell 130: 597-600.
24. Yu H, McDaid R, Lee J, Possik P, Li L, Kumar SM, et al. (2009) The Role of BRAF Mutation and p53 Inactivation during Transformation of a Subpopulation of Primary Human Melanocytes. Am J Pathol.
25. Haapajarvi T, Pitkanen K, Laiho M, (1999) Human melanoma cell line UV responses show independency of p53 function. Cell Growth Differ 10: 163-171.
26. Homer C, Knight DA, Hananeia L, Sheard P, Risk J, et al. (2005) Y-box factor YB1 controls p53 apoptotic function. Oncogene 24: 8314-8325.
27. Kruse JP, Gu W, (2009) Modes of p53 regulation. Cell 137: 609-622.
28. Tang Y, Luo J, Zhang W, Gu W, (2006) Tip60-Dependent Acetylation of p53 Modulates the Decision between Cell-Cycle Arrest and Apoptosis. Molecular Cell 24: 827-839.
29. Satyamoorthy K, Chehab NH, Waterman MJ, Lien MC, El-Deiry WS, et al. (2010) Aberrant regulation and function of wild-type p53 in radioresistant melanoma cells. Cell Growth Differ 11: 467-474.
30. Kastan MB, Berkovich E, (2007) p53: a two-faced cancer gene. Nat Cell Biol 9: 489-491.
31. Weisz L, Damalas A, Liontos M, Karakaidos P, Fontemaggi G, et al. (2007) Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells. Cancer Res 67: 2396-2401.
32. Dickopp A, Esche H, Swart G, Seeber S, Kirch HC, et al. (2000) Transformation-defective adenovirus 5 E1A mutants exhibit antioncogenic properties in human BLM melanoma cells. Cancer Gene Ther 7: 1043-1050.
33. Bakker ABH, Phillips JH, Figdor CG, Lanier LL, (1998) Killer Cell Inhibitory Receptors for MHC Class I Molecules Regulate Lysis of Melanoma Cells Mediated by NK cells, {gamma}{delta} T Cells, and Antigen-Specific CTL. J Immunol 160: 5239-5245.
34. Van Muijen GN, Cornelissen LM, Jansen CF, Figdor CG, Johnson JP, et al. (1991) Antigen expression of metastasizing and non-metastasizing human melanoma cells xenografted into nude mice. Clin Exp Metastasis 9: 259-272.
35. Riebeling C, Müller C, Geilen CC, (2003) Expression and regulation of phospholipase D isoenzymes in human melanoma cells and primary melanocytes. Melanoma Research 13.
36. Lehmann JM, Riethmuller G, Johnson JP, (1989) MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Acad Sci U S A 86: 9891-9895.
37. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, et al. (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439: 358-362.
38. Rongcun Y, Salazar-Onfray F, Charo J, Malmberg KJ, Evrin K, et al. (1999) Identification of New HER2/neu-Derived Peptide Epitopes That Can Elicit Specific CTL Against Autologous and Allogeneic Carcinomas and Melanomas. J Immunol 163: 1037-1044.
39. Becker JC, Dummer R, Hartmann AA, Burg G, Schmidt RE, (1991) Shedding of ICAM-1 from human melanoma cell lines induced by IFN-gamma and tumor necrosis factor-alpha. Functional consequences on cell- mediated cytotoxicity. J Immunol 147: 4398-4401.
40. Haferkamp S, Scurr LL, Becker TM, Frausto M, Kefford RF, et al. (2009) Oncogene-induced senescence does not require the p16(INK4a) or p14ARF melanoma tumor suppressors. J Invest Dermatol 129: 1983-1991.
41. Verhaegen M, Bauer JA, Martin dl V, Wang G, Wolter KG, et al. (2006) A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. Cancer Res 66: 11348-11359.
42. Smith SL, Shioda T, (2009) Advantages of COS-1 monkey kidney epithelial cells as packaging host for small-volume production of high-quality recombinant lentiviruses. Journal of Virological Methods 157: 47-54.
43. Wischhusen J, Naumann U, Ohgaki H, Rastinejad F, Weller M, (2003) CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death. Oncogene 22: 8233-8245.